Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
Blue curve MMWR spacer

Food and Drug Administration Approval of Use of Haemophilus b Conjugate Vaccine for Infants

The Food and Drug Administration has approved the Haemophilus b Conjugate Vaccine (Diphtheria CRM 197 Protein Conjugate) manufactured by Praxis Biologics, Inc., and distributed as HibTITERTM by Lederle Laboratories (Pearl River, New York) for use in infants in a three-dose immunization series at 2, 4, and 6 months of age. Previously unvaccinated infants 7-11 months of age should receive two doses 2 months apart. Previously unvaccinated children 12-14 months of age should receive one dose; a booster dose after 15 months of age is recommended for these children. Previously unvaccinated children 15-60 months of age should receive a single dose and do not require a booster. In the United States, Haemophilus influenzae type b is the major cause of bacterial meningitis in children less than 5 years of age, with the peak incidence in children less than 1 year of age (1). The principal efficacy trial for this vaccine was conducted in approximately 60,000 infants in the Northern California Kaiser Permanente Health Plan (2);approximately half of those children received the vaccine. Twelve cases of H. influenzae type b invasive disease occurred in unvaccinated children, compared with no cases in fully vaccinated children, indicating an efficacy of 100%, with the lower limit of the 95% confidence interval equal to 68%. The Immunization Practices Advisory Committee (ACIP) is planning to issue a complete statement. Reported by: Center for Biologics Evaluation and Research, Food and Drug Administration. Center for Infectious Diseases; Center for Prevention Svcs, CDC.


  1. Schlech WF, Ward JI, Band JD, et al. Bacterial meningitis in the United States, 1978 through 1981: the National Bacterial Meningitis Surveillance Study. JAMA 1985;253:1749-54. 2. Black SB, Shinefield HR, Hiatt RA, et al. Efficacy of HbOC conjugate Haemophilus influenzae type b vaccine in a study population of 48,000 infants (Abstract). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1990.

Disclaimer   All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to

Page converted: 08/05/98


Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A


Department of Health
and Human Services

This page last reviewed 5/2/01